Prostate Cancer International is
for 2011 by Great NonProfits
A poster to be presented at the upcoming ASCO annual meeting gives us some insights into the actual behaviors of physicians and their patients regarding the use of active surveillance today in the “real world” of clinical practice (as opposed to clinical trials and case series at academic medical centers).
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: active surveillance, low risk, Management | 4 Comments »
According to a media release issued late yesterday by Medivation and Astellas Pharma, Medivation has just submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval to market enzalutamide (a.k.a MDV3100).
Filed under: Uncategorized | 2 Comments »
According to an article by Andrew Pollack in today’s issue of the New York Times, a company called Osisris Therapeutics has achieved the first-ever approval to market a therapy based on stem cells — in Canada, for children with a condition known as graft versus host disease or GvHD, which is a well-recognized complication of [...]
Filed under: Uncategorized | Tagged: stem cells | Leave a Comment »
According to the abstract of a paper to be presented at the upcoming meeting of the American Society for Clinical Oncology in Chicago at the beginning of June, 24 weeks of treatment with neoadjuvant abiraterone acetate + prednisone + an LHRH agonist appears to be able to eliminate visible risk of prostate cancer in post-surgical [...]
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment, Uncategorized | Tagged: abiraterone, dutasteride, enzalutamide, leuprolide, MDV3100, neoadjuvant, pre-surgical | 6 Comments »
Malecare has just issued an updated version of its free book on recurrent and advanced prostate cancer. Many people have gained great benefit from the first edition of this book, and we are sure that the new version is equally useful.
Filed under: Living with Prostate Cancer, Management, Uncategorized | Tagged: advanced, book, Malecare, recurrent | 2 Comments »
For those who prefer to listen to their prostate cancer updates (as opposed to those that are happy to read) the video-based web site known as ProstateVideos.com has just completed a major overhaul.
Filed under: Uncategorized | Tagged: education, information, video | Leave a Comment »
According to a media report issued today, researchers at the University of Chicago have discovered that a product known as caffeic acid phenethyl ester or CAPE was able to stop the growth of prostate cancer tumors in a mouse model.
Filed under: Uncategorized | 2 Comments »
According to a media release from Vivus, Inc., issed late on Friday, the U.S. Food & Drug Administration has approved their PDE5 inhibitor avanafil (Stendra®) to the treatment of erectile dysfunction. However, we have to immediately point out that data on the activity of this drug in men who have been treated for prostate cancer [...]
Filed under: Uncategorized | Leave a Comment »
An article in the Journal of Translational Medicine (in conjunction with a media release from the University of Central Florida) has described a new test that — according to the media release — may be able to further discriminate between indolent and clinically significant forms of prostate cancer.
Filed under: Uncategorized | Leave a Comment »
The costs associated with the treatment of prostate cancer — particularly the more advanced forms of prostate cancer that require sophisticated forms of drug therapy — can be considerable. Patients often benefit from help and assistance in negotiating these costs and in handling the various needs of their physicians, their insurance companies, and Medicare or even Medicaid.
Filed under: Uncategorized | Tagged: cost, help, support | Leave a Comment »
Not surprisingly, a major urology organization (the Large Urology Group Practice Association or LUGPA) has aggressively disputed the findings recently published by Mitchell in Health Affairs regarding the numbers of prostate biopsies conducted by urology groups with in-house pathology laboratories (see earlier commentary).
Filed under: Uncategorized | Tagged: biopsy, cores, prostate | 2 Comments »
The U.S. Food & Drug Adminstration (FDA), yesterday, issued a statement about modifications to the labeling (the product prescribing information) for the two branded formulations of finasteride: Propecia® (finasteride 1 mg) and Proscar® (finasteride 5 mg). These modifications to the product labeling may be relevant to some men with or at risk for prostate cancer.
Filed under: Uncategorized | Tagged: adverse, effect, finasteride, side | Leave a Comment »
Most readers of this column will never have heard of Fred Gersh; a few may have spoken to him or e-mailed him or actually met him. Fred passed away early this morning as a consequence of metastatic, castration- and chemotherapy-refractory disease 23 years after his initial diagnosis with prostate cancer.
Filed under: Uncategorized | 10 Comments »
As regular readers will be aware, the Supreme Court of the United States (SCOTUS) had recently delayed any decision on a case related to the rights of Myriad Genetics to hold and enforce use patents related to the BRCA1 and BRCA2 genes associated with the diagnosis of specific subtypes of breast and ovarian cancer.
Filed under: Uncategorized | 6 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site